Security key
71902K402
CERO THERAPEUTICS HOLDINGS, INC. - Common Stock, par value $0.0001 per share (CERO)
CUSIP: 71902K402
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 156,980
- Total 13F value
- $798,684
- Share change
- -89,791
- SEC-reported price per share
- $5.09
- Number of holders
- 10
- Value change
- -$456,801
- Number of buys
- 4
- Number of sells
- 2
- Shares outstanding
- 1,268,697
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2025
Institutions
10
Top holders
10
CERO full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2025
Previous quarter: Q2 2025
CERO THERAPEUTICS HOLDINGS, INC. SEC filings
CERO THERAPEUTICS HOLDINGS, INC. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 71902K402
Recent filing periods:
Ownership snapshot
Top reported holders of CERO - CERO THERAPEUTICS HOLDINGS, INC. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Brian G. Atwood
Disclosed value leader
Stuart M. Sloan
Comparable rows
10/15
Latest evidence
30 Jun 2025
13D/G
3/4/5
13F
Lead comparable stake: 9.9%
5 rows are not safely comparable across share classes.
13D/G row: Brian G. Atwood
Showing 1-6 of 15 holder rows.
Quick read
Brian G. Atwood leads the comparable SEC ownership view at 9.9%.
10 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Brian G. Atwood's linked filing trail.
Comparable ownership
Top 5
Brian G. Atwood
9.9%
ARMISTICE CAPITAL, LLC
5%
YK Bioventures Opportunities GP I...
0.33%
ARCH Venture Management, LLC
1.8%
UBS Group AG
0.21%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Brian G. Atwood |
13D/G
|
9.9%
|
$20,472
511,800 shares
|
+$12,376 | 31 Mar 2025 |
| ARMISTICE CAPITAL, LLC |
13D/G
|
5%
|
$552,046
63,308 shares
|
$0 | 30 Jun 2025 |
| YK Bioventures Opportunities GP I, LLC |
3/4/5
13D/G
10%+ Owner
|
0.33%
from 13D/G
|
$780,310
13,005,169 shares
|
— | 11 Dec 2024 |
| ARCH Venture Management, LLC |
13F
Company
|
1.8%
|
$215,606
22,389 shares
|
— | 30 Jun 2025 |
| UBS Group AG |
13F
Company
|
0.21%
|
$25,279
2,625 shares
|
— | 30 Jun 2025 |
| FNY Investment Advisers, LLC |
13F
Company
|
0.08%
|
$10,000
1,050 shares
|
— | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
10
Shares
156,980
Rows available
10
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
8
Q3 2025 holders
10
Holder diff
2
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 value | Q3 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend